NEWS , Press release 2025.10.6  Rebirthel concludes Exclusive License Agreement for Patent on T Cell medicine for COVID-19 

Rebirthel concludes Exclusive License Agreement for Patent on T Cell medicine for COVID-19 with Kyoto University, Research Institute for Microbial Diseases of Osaka University, Fujita Health University, and the National Center for Child Health and Development .

For details, please see the press release below.